New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel's Seliciclib in Treating Breast Cancer Resistant to Hormone Therapy
February 17, 2010 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 17, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced that a newly published study demonstrates that the company's...
Cyclacel Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
February 01, 2010 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 1, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”) today announced that the...
Cyclacel Regains NASDAQ Compliance
January 27, 2010 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 27, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") today announced that NASDAQ notified the Company...
Cyclacel Completes Previously Announced Registered Direct Offering
January 25, 2010 16:01 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 25, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that it completed its...
Cyclacel to Raise Up to $7.9 Million in Registered Direct Offering
January 21, 2010 09:21 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 21, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”) announced today that it has...
Cyclacel Completes Previously Announced Registered Direct Offering
January 13, 2010 13:36 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 13, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that it completed its previously...
Cyclacel to Raise Up to $9.5 Million in Registered Direct Offering
January 11, 2010 09:10 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 11, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that it has entered into definitive...
Cyclacel's Seliciclib Found Effective Against Lung Cancer Cell Lines Including K-RAS Mutations
January 07, 2010 12:08 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 7, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of two peer-reviewed journal articles featuring the...
Cyclacel Pharmaceuticals to Present at OneMedForum 2010
January 06, 2010 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that Spiro Rombotis, President and Chief Executive Officer, will...
Cyclacel Announces Publication of Peer-Reviewed Journal Article Describing the Mechanism of Action of Seliciclib
December 30, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 30, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of an article that reviews and discusses the...